Table 1.
The acquisition of Wilms’ tumor 1 (WT1) antigen-specific cytotoxic T cells in patients with human leucocyte antigen class-A*24:02.
| G-CSF (75 μg of Filgrastim) 16–18 h Prior to Apheresis (N = 54) | Treated | Untreated | p-Value ¶ |
|---|---|---|---|
| 39 | 15 | ||
| Number of DCs in 1 course (mean ± SD) | 9.13 ± 2.42 × 107 | 8.64 ± 2.80 × 107 | p = 0.320 |
| Induction ratio of WT1-CTLs * after one course (%) # | 36 (92.3%) | 10 (66.7%) | p = 0.019 |
| Median level of WT1-CTLs * after one course (range) | 0.05% (0.01–0.33) | 0.06% (0.01–0.38) | p = 0.712 |
| Median growth rate of WT1-CTLs * between the 1st and 7th session (range) | 0.03% (−0.02–0.31) | 0.02% (−0.03–0.38) | p = 0.462 |
* WT1 antigen-specific cytotoxic T cells; # tetramer+/CD8+T-cells > 0.2%; ¶ Mann–Whitney U-test. G-CSF, granulocyte colony-stimulating factor; CTL, cytotoxic T cells.